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BACKGROUND: Atypical Spitz tumors (AST) are rare spitzoid melanocytic proliferations with an uncertain
malignant potential. ASTs have overlapping features of both Spitz nevi and spitzoid melanoma, and conse-
quently generate controversy with diagnosis and management. Sentinel lymph node biopsy (SLNB) has
been proposed as a possible means to gain additional insight into the true biologic potential of these
tumors; however, previous reports on the use of SLNB in ASTs have been limited by small numbers of
patients and short durations of follow-up. METHODS: The authors extracted data from their institution’s
prospective melanoma database, collected between 1994 and 2007, for all patients with ASTs of uncertain
biologic potential. They reviewed the clinical features of these patients, including the sentinel lymph node
status, and the histological features of the tumors. RESULTS: A total of 67 patients with ASTs were
identified, with a median age of 23.7 years. The mean depth was 2.4 mm. Of these, 57 had a SLNB per-
formed, with 27 (47%) having a positive sentinel lymph node. SLNB-positive cases had a significantly lower
mean age than SLNB-negative cases (17.9 vs 28.7 years; P ¼ .013); however, no other significant differences
were observed. All 27 patients with a positive SLNB were alive and disease free with median follow-up of
43.8 months. One patient who did not receive a SLNB developed recurrent disease with regional and dis-
tant metastases. CONCLUSIONS: ASTs do not appear to behave like conventional melanoma. There is a
high incidence of microscopic lymph node deposits in SLNBs, but despite this finding, patients have a
favorable prognosis. Our findings raise several questions regarding the malignant potential of ASTs, and
the role of SLNB in their management. Cancer 2009;115:631–41. VC 2009 American Cancer Society.
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Although most spitzoid melanocytic proliferations can be identified as either benign Spitz nevus or
spitzoid melanoma, a rare subset that is difficult to classify histologically also exists. These lesions contain
intermediate histologic features seen in both benign Spitz nevi and malignant melanoma, and subsequently
generate considerable uncertainty regarding their biological potential. These equivocal borderline lesions
were previously designated as malignant spindle and epithelioid cell nevi, malignant Spitz nevi,
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diagnostically controversial spitzoid melanocytic tumors,
atypical epithelioid melanocytic proliferations of
uncertain biologic potential, and atypical Spitz tumors.1-4
We currently favor the term atypical Spitz tumor of
uncertain biologic potential (AST) to describe such
lesions (Figs. 1 and 2).
Previous attempts to characterize ASTs histologi-
cally have identified several features, including: large size
(often>10 mm diameter), asymmetry, poor circumscrip-
tion, ulceration, deep growth often into subcutaneous fat,
greater degree of cytological atypia than seen in Spitz nevi
with significant nuclear pleomorphism, aberrant or sheet-
like dermal growth pattern with a high cellular density,
lack of maturation with increasing depth, and the pres-
ence of deep dermal mitoses.5 However, many of these
features are also seen in spitzoid melanoma, and subse-
quently the diagnosis is based on the assessment of the se-
verity and frequency of multiple histopathological factors
with clinicopathological correlation. Given the lack of de-
finitive diagnostic features, considerable disagreement
exists with little consensus among expert dermatopatholo-
gists and clinicians regarding both diagnosis and clinical
management.6
The difficulty and disagreement with diagnosis, and
the resulting uncertain biologic behavior and clinical
management, create considerable confusion for the
patient and the treating physician. This is further compli-
cated because often patients with AST are young, with a
lower likelihood of developing melanoma. Although
ASTs have generally been reported to have a good progno-
sis, there are well-documented cases of metastasis and
death.5,7 Because the malignant potential of ASTs
remains uncertain, most clinicians and patients decide to
treat more aggressively to avoid undertreating a poten-
tially lethal lesion. ASTs are generally treated in a similar
manner to melanoma, with a wide excision of the primary
lesion, and in many cases a sentinel lymph node biopsy
(SLNB).
The use of SLNB in atypical spitzoid melanocytic
proliferations has been reported in a total of 78
patients.4,8-16 Although it is unclear whether all of these
reports have included lesions that would be classified as
ASTs, they are all likely to be controversial and would
generate differing opinions regarding their malignant
potential. Of the 78 patients, 31 had a positive SLNB
(39%). Although there are previous reports of atypical
spitzoid melanocytic proliferations resulting in metastasis
and death, all 31 patients with a positive SLNB were alive
and disease free, with a mean follow-up of 29 months.
These prior studies suggest a good prognosis even with a
positive SLNB, but reported follow-up is relatively short,
precluding definite conclusions.
At our institution, we have typically treated ASTs
1 mm in depth or 0.75 to 0.99 mm with other adverse
FIGURE 1. An atypical Spitz tumor of uncertain biologic
potential from a 11-year-old girl is shown, with a Breslow
depth of 7.9 mm with a negative sentinel lymph node biopsy.
At scanning magnification, the lesion is symmetrical, being
well circumscribed with a wedge-shaped silhouette, an
expansile bulging growth pattern and pushing borders at the
base.
FIGURE 2. A section from the mid-dermis at high power in
the same patient as in Figure 1 shows epithelioid melanocytes
in a sheet-like growth pattern with deep mitoses present
(arrowheads).
Original Article
632 Cancer February 1, 2009
features, such as a high mitotic rate or ulceration, with
wide local excision and SLNB. It was once thought that
the SLNB status would provide useful information and
insight that may help better assess the true biologic poten-
tial of these tumors and allow for better counseling and
subsequent therapy.17 Our objective was to describe our
experience with ASTs, including the use of SLNB. This
series, which is the largest with the most complete long-
term follow-up reported to date, provides a unique oppor-
tunity to re-evaluate what a positive SLNB means in this
context and to propose a therapeutic algorithm for man-
agement of these problematic lesions.
MATERIALS AND METHODS
Study approval was obtained from the institutional review
board of the University of Michigan Medical School. We
queried our prospectively collected melanoma database
for all cases of spitzoid melanocytic proliferations between
1994 and 2007. The medical records were reviewed, and
those with a diagnosis of an atypical Spitz tumor or spit-
zoid melanocytic proliferation of uncertain biologic
potential were selected for analysis. The diagnosis was ren-
dered by at least 1 of our 4 board-certified dermatopathol-
ogists, and each diagnosis was recorded. If a diagnosis was
given by a dermatopathologist outside our institution
who had recognized expertise in melanocytic pathology,
their diagnosis was recorded as well. We extracted clinical
parameters from the medical record, including: age, sex,
family history of melanoma, history of immunosuppres-
sion, prior severe sunburns, history or presence of dysplas-
tic nevi, lesion location, lesion color and shape, SLNB
status if performed, complete lymph node dissection
(CLND) status if performed, and any adjuvant therapy
used. Histopathologic parameters recorded included: the
lesion depth, Clark level, presence of nuclear pleomor-
phism, presence of deep dermal or marginal mitoses,
incomplete maturation, and confluent or aberrant dermal
growth pattern. In patients who had an SLNB performed,
location, number of positive and negative nodes, status of
hematoxylin and eosin (H&E) stained sections, S-100
and Melan-A immunostaining on the SLNB, and pres-
ence or absence of capsular nodal nevi were recorded. The
positive SLNB slides were retrieved and reviewed by 1
board-certified dermatopathologist. Location of the tu-
mor deposit (subcapsular, parenchymal, or both), size
expressed in percentage of the lymph node surface area
(<1%, 1%-10%,>10%), largest dimension of the largest
deposit in millimeters (<0.2 mm, 0.2-2 mm, >2 mm),
number of cells within the largest aggregate (<10, 10-50,
>50 cells), cell morphology (epithelioid, spindle or both),
presence of pigmentation, and presence and morphology
of capsular nevi were recorded. Because mitotic figures
within the SLN tumor deposit were rare, a formal mitotic
count was not performed. To perform further analysis on
the SLN characteristics, if the patient had more than 1
positive SLN, the most severe or largest variable was used.
The SLNB technique and the method of SLN evaluation
have been described previously.18,19 If a CLND was per-
formed, location and number of positive and negative
nodes were recorded. Follow-up data were obtained from
the medical record or by contacting the patient or the re-
ferring physician to obtain the most current disease status.
Statistical Analysis
TheWilcoxon rank sum test was used to assess the associa-
tion between a continuous variable (such as age at diagno-
sis) and a 2-level categorical variable (such as SLNB
status). The Kruskal-Wallis statistic was used to test the
association between a continuous variable and a categori-
cal variable with more than 2 levels. The chi-square and
Fisher exact test were used to assess the association
between categorical variables, as appropriate. The Spear-
man rank correlation coefficient was used to assess the
association between continuous and ordered variables.
Overall survival was defined as the time to either last fol-
low-up or death from any cause. Time to recurrence was
defined as time to recurrence of the atypical Spitz tumor,
and subjects whose tumor did not recur were censored.
Survival estimates were calculated using the Kaplan-Meier
method. A P value of .05 or less is considered to be statisti-
cally significant, and all of the tests are 2-sided.
RESULTS
The clinical and histopathological features are summar-
ized in Table 1. We identified 67 patients from January
1994 to August 2007 with a diagnosis of an AST. The me-
dian age of the patients was 23.7 years, ranging from 1.7
to 65 years. Forty-one patients were female, 26 were male.
The most common location of the primary lesion was the
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leg (30%), followed closely by the head and neck (28%),
trunk (22%), arm (16%), and foot (3%). The majority of
the lesions were amelanotic with a pink or red color
(51%), and the primary lesion was raised in 69% of cases.
The original lesion was congenital in 4 patients (6.0%).
A positive family history of melanoma was present
in 8 patients (12%); none was immunosuppressed. A his-
tory of prior blistering or peeling sunburn was reported in
43 (64%), and 41 (61%) had Fitzpatrick skin types I-III.
The majority of patients had no history of dysplastic nevi
(94%), nor clinical presence of dysplastic nevi (78%).
Fifty-nine of the 67 cases were reviewed by 2 or
more UM dermatopathologists, with 25 reviewed by 2
dermatopathologists, 32 by 3, and 2 by 4. A concordant
diagnosis was reached in 38 (64%). Of the 21 (36%) cases
with discordance, the alternative diagnoses included
atypical Spitz nevus in 35% and spitzoid melanoma in
65%. The depth ranged from 0.3 mm to 8 mm (mean,
2.4 mm). The Clark level was recorded for 42 patients; 33
were Clark level IV (49%). Nuclear pleomorphism was
present in 24 (36%) cases, deep dermal or marginal mito-
ses were present in 47 (70%), lack of maturation with
increasing depth in 35 (52%), and an aberrant dermal
growth pattern in 28 (42%) (Figs. 1-6)
The clinical management is summarized in Figure
7. Six patients had primary lesions with a depth <1 mm,
or 0.75 to 0.99 mm with no other adverse features, and
were treated with wide local excision (WLE) alone, usually
with a 1-cm margin. The remaining 61 patients had
lesions that were considered to be suitable for SLNB
counseling, with depth of 1 mm, or 0.75 to 0.99 mm
with other adverse features such as the presence of
ulceration, a high mitotic rate, or a young age.19,20 Of
these 61 patients, 57 underwent wide local excision and
SLNB, whereas 4 received wide local excision alone. One
of the 4 WLE-only group was an 18-month-old infant







Female 41 17 24
Male 26 18 8
Color
Pink/red 34 19 15
Brown/back 17 8 9
Other 5 2 3
Unknown 11 6 5
Lesion shape
Raised 46 27 19
Flat 3 1 2
Unknown 18 7 11
Location
Head and neck 19 12 7
Trunk 15 9 6
Arms 11 5 6
Legs 20 9 11
Feet 2 0 2
Breslow depth, mean mm 2.4 2.6 2.1
Clarks Level
II 3 0 3
III 4 1 3
IV 33 16 17
V 2 2 0
Unknown 25 16 9
Pleomorphism
Present 24 13 11
Absent 33 14 19
Unknown 10 8 2
Dermal mitoses
Present 47 25 22
Absent 3 1 2
Unknown 17 9 8
Maturation with depth
Present 35 19 16
Absent 26 11 15
Unknown 6 5 1
Aberrant growth pattern
Present 28 15 13
Absent 39 20 19
Unknown 0 0 0
FIGURE 3. An atypical Spitz tumor of uncertain biologic
potential from a different 11-year-old girl is shown, with a Bre-
slow depth of 1.45 mm. The sentinel lymph node biopsy was
positive, with <1% surface area involved. The lesion is well cir-
cumscribed and symmetrical, yet lacks maturation.
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whose parents decided against performing a SLNB after
discussion of the potential benefits and risks of the proce-
dure. Of the remaining 3 WLE-only group, all were
treated at a different institution, and 2 of these were lost
to follow-up.
Figure 8 summarizes the SLNB findings. A positive
SLNB was identified in 27 (47%) of 57 who received a
SLNB. Of these 27, 17 had deposits present in 1 SLN, 7
had deposits in 2 SLNs, and 3 had deposits in 3 SLNs.
FIGURE 4. At high power, the junctional component from the
same patient as in Figure 3 shows some features seen in typi-
cal Spitz nevi, with epidermal hyperplasia and Kamino bodies
(asterisk)
FIGURE 5. An atypical Spitz tumor of uncertain biologic
potential from an 8-year-old boy is shown, with a Breslow
depth of 3 mm. The sentinel lymph node biopsy was positive,
with effacement of the lymph node. At scanning magnifica-
tion, there are some Spitz nevus-like features, with good cir-
cumscription, epidermal hyperplasia, and mild dermal
papillary edema.
FIGURE 6. Spindle and epithelioid melanocytes in the deep
dermis of the same patient as in Figure 5 show slight nuclear
pleomorphism, a sheet-like growth pattern, and lack of
maturation.
FIGURE 7. Clinical management of patients with atypical
Spitz tumor of uncertain biologic potential is represented.
Adverse features considered include: ulceration, high mitotic
rate, and young age. SLNB indicates sentinel lymph node
biopsy.
FIGURE 8. An overview is shown of the sentinel lymph node
biopsy findings and subsequent lymph node dissection. SLNB
indicates sentinel lymph node biopsy.
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Additional negative SLNs obtained at the time of SLNB,
ranging from 1 to 4 in number, were removed in 17
patients (63%). All 27 with a positive SLNB underwent a
CLND of the involved regional nodal basin. One (4%)
patient had 1 additional non-sentinel lymph node deposits.
The microscopic SLN deposits were visible using
H&E staining in 23 (85%) patients. Of the remaining 4
with a negative H&E but positive immunostaining, S-
100 and Melan-A were both positive in 3, and Melan-A
was positive alone in 1. Benign capsular nodal nevi were
present in 8 (14%) patients. A total of 37 of the 40 posi-
tive SLNBs were available for histological review, and
their findings are summarized in Table 2. SLN tumor
deposits were more frequently located in the subcapsular
sinus (41%) than the parenchyma (30%) or both loca-
tions (30%). Most of the SLN deposits had an epithelioid
cell morphology (68%), and were not pigmented (73%).
The majority of the SLN deposits had an atypical cytolog-
ical appearance similar to the primary cutaneous lesion,
with abundant cytoplasm and prominent nucleoli. Most
of the SLN tumor deposits were small, with 84%
involving<1% of the surface area of the SLN, 62% being
<0.2 mm in size, and 49% containing <10 cells (Fig. 9).
One patient had a SLN deposit involving greater than
10% of the lymph node surface area (Fig. 10). Only 3 of
the positive SLNs contained nodal nevi, with 1 having a
spitzoid morphological appearance. There were no signifi-
cant associations found between the patient and primary
tumor characteristics and the various positive SLN varia-
bles. A trend was observed with a younger age at diagnosis
Table 2. Histological Features of Positive Sentinel Lymph Nodes
SLN Parameter Frequency Percentage (%)
Location within lymph node
Subcapsular sinus 15 41%
Parenchymal 11 30%












Size of largest tumor aggregate
<0.2 mm 23 62%
0.2-2 mm 13 35%
>2 mm 1 3%
Only isolated tumor cells present
Yes 7 19%
No 30 81%
Size of largest tumor aggregate (total number of cells)
<10 cells 18 49%
10-50 cells 12 32%
>50 cells 7 19%
Capsular nevus
Ordinary morphology 2 5%
Spitzoid morphology 1 3%
None 34 92%
SLN indicates sentinel lymph node.
Original Article
636 Cancer February 1, 2009
being associated with an epithelioid and spindle cell mor-
phology; however, this did not reach statistical signifi-
cance (P¼ .073).
The differences between the SLNB-positive and
-negative groups are summarized in Table 3. Seventeen
(63%) of 27 patients with a positive SLNB were female;
10 (37%) were male. Seventeen (57%) of 30 patients with
a negative SLNB were female; 13 (43%) were male. The
depth of the positive SLNB group ranged from 1.1 to
8 mm (mean, 2.9 mm), whereas the negative SLNB group
ranged from 0.8 to 5.5 mm (mean, 2.3 mm). No signifi-
cant differences were seen between SLNB-positive and
-negative cases in the frequency of nuclear pleomorphism
(41% vs 33%), deep dermal mitoses (63% vs 80%), lack
of maturation with increasing depth (48% vs 63%), and
aberrant dermal growth pattern (41% vs 43%). Patient
age was found to be the only significant difference
between the 2 groups, with SLNB-positive cases having a
mean age of 17.9 years (range, 2.9-50.1 years) and SLNB-
negative cases 28.7 years (range, 2.3-65.3 years) (P ¼
.013). Adjuvant therapy was administered to 24 (89%) of
the 27 patients with a positive SLNB. Adjuvant inter-
feron-a2b was used in 23, and an adjuvant vaccine was
used in 1. One patient with a negative SLNB received ad-
juvant interferon-a2b at a different institution.
The Kaplan-Meier estimated median follow-ups
were as follows: for the SLNB-positive group it was
43.8 months (range, 32.4-57.3 months), for the SLNB-
negative group it was 28.6 months (range, 19.8-47.0
months), and for theWLE-only group it was 32.5 months
(range, 7.1-57.0 months). All patients in the SLNB-posi-
tive and -negative groups were alive and disease free at the
last point of follow-up. One patient who was a candidate
for an SLNB but was treated with wide excision alone
developed recurrent disease with regional and distant me-
tastases, and died from disease. Seven of 9 treated with
wide excision alone were alive and disease free, with 2
treated at an outside institution lost to follow-up.
The only case of recurrent disease occurred in a 46-
year-old woman treated with WLE alone at a different
institution. She was diagnosed with a Spitz nevus by 3 der-
matopathologists at an outside facility. The lesion was
excised, but extended to 1 peripheral margin, and close
observation was recommended. She was seen at our insti-
tution 2 years after her excision, presenting with a palpa-
ble left inguinal lymph node metastasis. The original
biopsy was reviewed and interpreted as an atypical Spitz
tumor with a depth of 1.1 mm. She was treated with a
CLND and adjuvant interferon. She subsequently devel-
oped brain and lung metastases and died from disease
approximately 3 years after initial diagnosis.
DISCUSSION
In this analysis of ASTs, we observed a high incidence of
positive SLNB (47%). Despite this high incidence, within
the total cohort, only 1 case of recurrent disease was
FIGURE 10. Spindle and epithelioid melanocytes involve
>10% of the lymph node and partially efface the sentinel
lymph node parenchyma (arrowhead), with Melan-A immuno-
stain section (inset) from the same patient as in Figures 5
and 6.
FIGURE 9. A few atypical epithelioid melanocytes within the
parenchyma of the sentinel lymph node from the same patient
as in Figure 3 are visible on hematoxylin and eosin (arrow-
head) and with positive Melan-A immunostaining (inset).
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observed, which led to death from disease. SLNB was
offered to patients with ASTs based on the initial hypothesis
that it may provide further prognostic information regard-
ing the malignant potential and classification of the lesion.17
Initially, it was proposed that if metastatic disease was found
in the SLNB, this provided evidence that the original, bor-
derline lesion was indeed malignant; whereas a negative
SLNBwould favor a benign lesion.17 However, our findings
raise several questions regarding the malignant potential of
ASTs, and the use of SLNB in their classification, prognosis,
and subsequent clinical management.
The histologic interpretation of SLNB in melano-
cytic lesions can be challenging. In conventional mela-
noma, the presence of cytologically atypical melanocytes
within the parenchyma or subcapsular sinuses of the
lymph node is usually considered to represent metastatic
disease. These cells have been shown to have chromo-
somal aberrations consistent with malignancy, supporting
this interpretation.21 In ASTs, the presence of melano-
cytes within the parenchyma or subcapsular sinuses of the
lymph node has also been commonly interpreted as evi-
dence for malignant metastasis. Although the pattern of
lymph node metastatic deposits is well known for conven-
tional melanomas, it remains to be fully characterized for
ASTs. This has led some investigators to question the bio-
logic significance of SLN involvement in AST, and
whether they are biologically analogous to those from
melanoma.22,23 Some benign melanocytic proliferations,
such as cellular blue nevi, have been shown to have benign
lymph node deposits within the parenchyma or subcapsu-
lar sinuses.24-27 In addition, whereas most benign nodal
nevi are found in the capsule or trabeculae of the lymph
node, there are rare reports of intraparenchymal nodal
nevi.26,27 Although the origin of benign nodal nevi is
unknown, it is suggested that they may result from migra-
tion of benign melanocytes from cutaneous nevi.28,29 It is
also possible that they represent primary benign remnants
or rests of development within the lymph node. On the
basis of these observations, it is conceivable that parenchy-
mal and subcapsular sinus lymph node deposits found in
ASTs may represent a benign process, analogous to those
deposits seen in cellular blue nevi. The high incidence of a
positive SLNB and the excellent survival observed in our
study would be consistent with this possibility.
Although previous studies of SLNB in controversial
spitzoid melanocytic proliferations have reported no
instances of systemic metastatic disease, even with a posi-
tive SLNB, they have been limited by short follow-up
intervals (12-34 months).4,13-16 Similarly, we also
observed no disease recurrence in all patients who under-
went an SLNB. In addition, the larger numbers and lon-
ger follow-up data in our study allow us to make some
interesting comparisons to melanoma. In the Multicenter
Selective Lymphadenectomy Trial (MSLT-1) the 5-year
disease-free survival for SLNB-positive melanoma was
59%, and the 5-year melanoma-specific survival was
72.3%.30 By comparison, all of our SLNB-positive ASTs
patients are disease-free, with a median follow-up of
43.8 months (3.65 years). However, the mean age of the
MSLT-1 patients was 49 years, compared with 17.9 years
in our SLNB-positive group. As melanoma survival is
Table 3. Analysis of Differences Between SLN-Positive
and -Negative Cases
Total SLN1 SLN2 P Value*
Number 57 27 30
Sex .79
Female 34 17 17
Male 23 10 13
Age, y 23.7 17.9 28.7 .013y
Breslow depth, mean mm 2.4 2.9 2.3 .13y
Clark level .076
III 3 0 3
IV 31 14 17
V 2 2 0
Unknown 21 11 10
Pleomorphism >.99
Present 21 11 10
Absent 27 13 10
Unknown 9 3 6
Dermal mitoses .57
Present 41 17 24
Absent 3 2 1
Unknown 13 8 5
Maturation with depth .40
Present 32 13 19
Absent 20 11 9
Unknown 5 3 2
Aberrant growth pattern >.99
Present 24 11 13
Absent 33 16 17
Unknown 0 0 0
SLN indicates sentinel lymph node.
All P values are calculated excluding the unknown category.
* Fisher exact test unless noted otherwise.
yCalculated using Wilcoxon rank sum test.
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known to decrease with increasing age,31 a comparison
with a younger melanoma population maybe more mean-
ingful. In patients aged 1 to 19 years from the National
Cancer Database, the 5-year overall survival for patients
with regional metastatic melanoma was 68%.32 By com-
parison, ASTs appear to have a better prognosis than con-
ventional melanoma, even in younger populations. This
suggests that some ASTs may be benign or behave in a
more indolent fashion when compared with melanoma.
Longer follow-up of 5 to 10 years is still required to fully
evaluate the frequency of late recurrence.
We found that a positive SLNB was significantly
associated with decreasing age, which is similar to what
has been described in conventional melanoma.19,20,31 In
conventional melanoma, decreasing age is associated with
an improved prognosis, despite the increased incidence of
positive SLNB.19,20,31 It has been hypothesized that
SLNB in younger patients detects a greater proportion of
micrometastatic deposits that are clinically insignificant,
possibly because of a more intact immune system that is
able to eliminate micrometastatic deposits and prevent
further metastasis from occurring.31 The excellent out-
comes in our study could be explained by a similar mecha-
nism, whereby the intraparenchymal melanocytic
deposits seen in ASTs are malignant metastases, but are
biologically inconsequential. Alternatively, it remains pos-
sible that in some, the micrometastatic deposits are clini-
cally significant, and the SLNB itself was therapeutic. We
did observe 1 patient who developed regional and then
distant metastases, which illustrates that some ASTs are le-
thal and are capable of both biologically significant lym-
phatic and hematogenous metastasis. Given that the only
example of distant metastases in our series was in a patient
who did not undergo an SLNB, the possibility that the
SLNB itself may be of therapeutic benefit remains.
Given the dilemma in interpretation of both the his-
tology of the primary cutaneous lesion and the SLNB, a
diagnostic test that could determine the malignant poten-
tial with high sensitivity and specificity would be invalu-
able. Various methods have been investigated, including
the Ki-67 proliferation index, p-53, bcl-2, fatty acid syn-
thase expression, and loss of heterozygosity.33-35 Compar-
ative genomic hybridization (CGH) is a molecular
technique that determines DNA copy number gains and
losses. By using CGH, Bastian et al reported that 80% of
Spitz nevi have no copy number gains, and 20% have a
gain of chromosome 11p.36 This corresponds to the site
of the H-RAS gene, which is mutated in 67% of cases.37
By comparison, melanoma often has multiple copy num-
ber changes, including gain of chromosome 1q, 2, 6p, 7,
8q, 17, and 20 and loss of chromosome 6q, 8p, 9, and
10.38,39 Given these differences, CGH may be able to
determine the malignant potential of a controversial
lesion. As the CGH profile of spitzoid melanoma with a
malignant clinical course is not yet known, it is not defini-
tive whether CGH will accurately predict the clinical
behavior of ASTs. However, this technique holds promise
and warrants investigation in validation series with com-
plete clinical information and follow-up.
On the basis of the current knowledge in the field,
the optimal management strategy for ASTs remains chal-
lenging and controversial. On the basis of our interpreta-
tion of the best available evidence, we currently
recommend that ASTs be excised most commonly with a
1-cm margin to ensure complete removal to prevent local
recurrence. The decision as to whether to perform an
SLNB is more difficult. We presently counsel patients
and families regarding the potential risks and benefits
of SLNB for ASTs with a depth of 1 mm, or 0.75 to
0.99 mm with other adverse features.19,20 Although our
results suggest that some SLNB deposits may be benign or
clinically insignificant, a negative result is reassuring to
patients and alleviates distress, and the possibility remains
that SLNB itself may have therapeutic value.
If a positive SLNB shows a larger tumor burden
with involvement of>1% of the lymph node surface area
and/or with effacement of the lymph node architecture,
we consider the lesion more likely to be malignant and
counsel regarding CLND and adjuvant therapy. If the
SLNB contains only a few microscopic deposits of intra-
parenchymal melanocytes with <1% lymph node surface
area involvement, the question of proceeding with CLND
and adjuvant therapy remains controversial. In our analy-
sis, 59% of patients with a positive SLN had additional
negative SLNs, and only 1 had a positive nonsentinel
lymph node on CLND, suggesting that most patients do
not have a large number of additional lymph nodes
involved with tumor. In addition, CLND is associated
with greater morbidity than SLNB.40-42 Because benign
spitzoid proliferations are more common in children and
adolescents compared with adults, we use an age-based
approach toward the management of a minimally
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involved SLN. If the patient is20 years and has<1% of
the lymph node involved, we believe that closely observing
the regional nodal basin clinically is a reasonable option
after extensive counseling. In addition, serial ultrasound
may be beneficial to monitor the nodal basin. If the
patient is >20 years and has <1% of the lymph node
involved, we discuss the option of observation, but main-
tain a lower threshold for considering a CLND, given the
higher incidence of melanoma in this population.
In conclusion, ASTs do not appear to behave like
conventional melanoma. There is a high incidence of mi-
croscopic intraparenchymal deposits in SLNs, but despite
this finding, patients have a favorable prognosis. Although
it seems likely that many of these SLN deposits may
actually represent benign deposits or clinically insignifi-
cant malignant metastases, some of these deposits may be
clinically significant malignant metastases, albeit from a
more indolent melanoma variant. Although in many cases
the SLN status does not help determine the true biologic
potential of the lesion, a role for SLNB still exists, and it is
possible that the SLNB is therapeutic for some patients
who have malignant disease. Many questions remain
unanswered, and future science, particularly at the molec-
ular level, will certainly change the evolving management
for AST.
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